Bob Tribe joined the Therapeutic Goods Administration (TGA), Australia in 1971 as a GMP inspector after having worked in the pharmaceutical industry in a senior Quality Assurance position. He became Chief GMP Inspector in 1980, a position he held until his retirement in 2004. While at TGA he was elected Chairman of PIC/S in 2000-2001.
After retiring from TGA he established “Bob Tribe Consulting” and has assisted many GMP regulatory authorities around the world reach the PIC/S level of regulatory control. Of the sixteen regulatory authorities that he has assisted to date, ten have obtained PIC/S membership. He also consults to pharmaceutical manufacturers wishing to achieve compliance with PIC/S GMP requirements.
Bob is a member of the WHO Expert Committee on Specifications for Pharmaceutical Preparations and undertakes GMP inspections for the WHO under its Pre-qualification Programme.
Bob is the ISPE Regulatory Affairs Advisor for the Asia-Pacific region.
The 2025 ISPE Singapore Conference and Exhibition, hosted by the ISPE Singapore Affiliate, took place 27–29 August at Suntech Singapore. It is one of the largest and most well-regarded events for...
This year, the ISPE Singapore Affiliate proudly marks 25 years of advancing pharmaceutical engineering and technology. It has played a pivotal role in shaping the pharmaceutical and biopharmaceutical industries in the region, fostering a strong community focused on education, collaboration, and innovation. As we reach this remarkable milestone, we reflect on the journey and look ahead to an...
This virtual ISPE Global Pharmaceutical Regulatory Summit, held on 28 April 2021, brought together eleven regulators from different parts of the world to discuss how their approach to GMP inspections have adapted to the COVID-19 pandemic. Such a large number of regulators at a single forum is unprecedented for ISPE.